文献速递淋巴瘤

芬兰2007至2019年间结内外周T细胞淋巴瘤:发病率、晚期疾病负担与生存

Nodal peripheral T-cell lymphoma in Finland between 2007 and 2019: Incidence, late morbidity and survival.
PubMed 文献 · Br J Haematol · 2025-07-10

该研究利用芬兰四个全国性医疗登记数据,比较2007至2019年诊断的998例结内外周T细胞淋巴瘤(PTCL)患者与匹配对照,分析发病率、亚型分布、晚期疾病负担和生存。PTCL非特指型最常见,年均发病率0.62(0.45-0.87)/10万。患者预后差,无论年龄,合并症风险均显著高于对照。

要点

  • PTCL非特指型最常见,年均发病率0.62(0.45-0.87)/10万。
  • 1年生存率:<70岁组34%,≥70岁组49%。
  • 年轻和老年组肺炎、血栓风险均显著高于对照。

核心结论

  • 结内PTCL预后差,无论年龄,患者合并症风险均显著高于对照。
  • 作者认为需要靶向且毒性更低的治疗方式。

研究设计与样本

  • 研究比较了2007至2019年诊断的998例结内PTCL患者与匹配对照。
  • 数据来自四个全国性芬兰医疗登记库。

主要发现

  • PTCL非特指型最常见,年均发病率0.62(0.45-0.87)/10万。
  • 1年生存率:<70岁组34%,≥70岁组49%。
  • 年轻组诊断后慢性心力衰竭风险增加(HR 4.17 [2.16-8.05];p < 0.001)。
  • 肺炎风险:年轻组HR 6.47(4.40-9.53;p < 0.001),老年组HR 2.78(2.010-3.859;p < 0.001),均高于对照。
  • 血栓风险:年轻组HR 16.09(4.22-61.39;p < 0.001),老年组HR 5.34(2.33至NA;p < 0.001),均高于对照。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Data on late morbidity and survival in nodal peripheral T-cell lymphoma (PTCL) are scarce. This study investigated the incidence, subtype distribution, late morbidity and survival outcomes of nodal PTCL in Finland. The study compared 998 patients with nodal PTCL diagnosed between 2007 and 2019 with matched controls. Data from four nationwide Finnish healthcare registries were used. PTCL not otherwise specified was the most common subtype, with a mean annual incidence of 0.62 (0.45-0.87) per 100 000. The 1-year survival was 34% for patients aged <70 years and 49% for those aged ≥70 years. In the younger group, an increased risk of chronic heart failure (hazard ratio [HR], 4.17 [2.16-8.05]; p < 0.001) was observed after PTCL diagnosis. The risks of pneumonia (HR, 6.47 [4.40-9.53]; p < 0.001 and HR, 2.78 [2.010-3.859]; p < 0.001) and thrombosis (HR, 16.09 [4.22-61.39]; p < 0.001 and HR, 5.34 [2.33 to NA]; p < 0.001) were significantly higher in the younger and older age groups than that in controls. The prognosis of nodal PTCL is poor, and patients have a significantly higher risk of comorbidities than controls, irrespective of age. Therefore, targeted and less toxic treatment modalities are required.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Partanen A, Rönkä A, Anttalainen A, et al. Nodal peripheral T-cell lymphoma in Finland between 2007 and 2019: Incidence, late morbidity and survival. Br J Haematol. 2025. PMID: 40641050. doi:10.1111/bjh.20253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。